1. Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients
- Author
-
Nicola Tarantino, Domenico G. Della Rocca, Fengwei Zou, Aung Lin, Andrea Natale, and Luigi Di Biase
- Subjects
2019-20 coronavirus outbreak ,medicine.medical_specialty ,complications ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Arrhythmias, Cardiac ,Arrhythmias ,outcomes ,Ventricular tachycardia ,medicine.disease ,Article ,Tachycardia ,Physiology (medical) ,Internal medicine ,Prevalence ,Cardiology ,Humans ,Medicine ,ventricular tachycardia ,Cardiology and Cardiovascular Medicine ,business ,management - Abstract
Synopsis We review the current data on epidemiology, the clinical significance, the pathophysiologic mechanisms, and the treatment of VAs in the setting of COVID-19. VAs prevail in 0.15-8% of in hospitalized patients, but only sustained and rapid tachyarrhythmias are purportedly associated with a significant increase in mortality. Multiple factors can elicit VAs, which are ultimately deemed to be a marker of severe systemic disease rather than a distinct cardiac condition. Even though the electrophysiologist plays a determinant role in the secondary prevention of VAs, a multidisciplinary approach is indispensable for primary prophylaxis and acute management.
- Published
- 2022